PhD- National Institutes for Health and Medical Research – Pitie-Salpetriere University Hospital – Paris, France
Professor Chapman is Director Emeritus of the Dyslipidemia and Atherosclerosis Research Unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière University Hospital in Paris, France, which he directed from 1988 to 2014. He is equally Research Professor at the Medical Faculty of the Pierre and Marie Curie University, Paris. John Chapman is a longstanding European Atherosclerosis Society (EAS) member and was EAS President from 2009 to 2014. Together with Professor Henry Ginsberg, he has spearheaded the EAS Consensus Panel initiatives, which have been focused to date on Lipoprotein(a), on high Triglyceride/Low HDL dyslipidemia, on Statin intolerance, and on Familial Hypercholesterolemia; these publications have achieved wide visibility. As a member of the ESC/EAS Joint Task Force, he participated in the formulation of the 2011 Guidelines for Management of Dyslipidemia. John Chapman is presently Associate European Editor of “Arteriosclerosis, Thrombosis and Vascular Biology” and “Pharmacology and Therapeutics”.
He received his B.Sc. (Hons) degree at the University of Aberdeen, Scotland, and his Ph.D. degree in Medical Biochemistry at the Middlesex Hospital Medical School, University of London.
Professor Chapman serves on several international Advisory Boards and on Steering Committees of clinical intervention trials aimed at development of novel therapeutic approaches to attenuate dyslipidemia and atherosclerotic vascular disease. Professor Chapman is Laureate of the European Lipid Science Award for 2014, and of the 2015 Antonio M. Gotto Jr Prize in Atherosclerosis Research from the International Society of Atherosclerosis.